Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Tax Relief for American Families and Workers Act of 2024
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Tax Relief for American Families and Workers Act of 2024
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
IGM BIOSCIENCES, INC. via IGM BIOSCIENCES, INC.
2024 · third_quarter · Q3
H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IGM BIOSCIENCES, INC. via IGM BIOSCIENCES, INC.
2024 · second_quarter · Q2
Source: Senate LDA
Tax Relief for American Families and Workers Act of 2024
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Prohibiting Foreign Access to American Genetic Information Act of 2024
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Prohibiting Foreign Access to American Genetic Information Act of 2024
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Prohibiting Foreign Access to American Genetic Information Act of 2024
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Fiscal Responsibility Act of 2023
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Fiscal Responsibility Act of 2023
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Fiscal Responsibility Act of 2023
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Preparing for All Hazards and Pathogens Reauthorization Act
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Preparing for All Hazards and Pathogens Reauthorization Act
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Preparing for All Hazards and Pathogens Reauthorization Act
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Consolidated Appropriations Act, 2023
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023 FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023 FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023 FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan
Department of Defense Appropriations Act, 2023
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023 FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023 FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023 FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan
Consolidated Appropriations Act, 2022
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act
Consolidated Appropriations Act, 2022
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing
Consolidated Appropriations Act, 2023
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Food and Drug Amendments of 2022
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act
Food and Drug Amendments of 2022
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023
Food and Drug Amendments of 2022
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Department of Defense Appropriations Act, 2023
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023
Department of Defense Appropriations Act, 2023
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Department of Defense Appropriations Act, 2023
Client: IGM BIOSCIENCES, INC. · Firm: IGM BIOSCIENCES, INC.
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023
H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IGM BIOSCIENCES, INC. via IGM BIOSCIENCES, INC.
2024 · first_quarter · Q1
Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IGM BIOSCIENCES, INC. via IGM BIOSCIENCES, INC.
2023 · fourth_quarter · Q4
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IGM BIOSCIENCES, INC. via IGM BIOSCIENCES, INC.
2023 · third_quarter · Q3
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IGM BIOSCIENCES, INC. via IGM BIOSCIENCES, INC.
2023 · second_quarter · Q2
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IGM BIOSCIENCES, INC. via IGM BIOSCIENCES, INC.
2023 · first_quarter · Q1
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023 FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IGM BIOSCIENCES, INC. via IGM BIOSCIENCES, INC.
2022 · fourth_quarter · Q4
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IGM BIOSCIENCES, INC. via IGM BIOSCIENCES, INC.
2022 · third_quarter · Q3
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IGM BIOSCIENCES, INC. via IGM BIOSCIENCES, INC.
2022 · second_quarter · Q2
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IGM BIOSCIENCES, INC. via IGM BIOSCIENCES, INC.
2022 · first_quarter · Q1
H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IGM BIOSCIENCES, INC. via IGM BIOSCIENCES, INC.
2021 · fourth_quarter · Q4
Issues relating to the development of antibody therapy for COVID-19. Issues related to supply chain and biopharmaceutical manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IGM BIOSCIENCES, INC. via IGM BIOSCIENCES, INC.
2021 · fourth_quarter · RR
Issues relating to the development of antibody therapy for COVID-19